Table 2.
combinations of checkpoint inhibitors in clinical trails.
| Checkpoint inhibitors | Patients enrolled | Clinical setting | phase | NCT numbers | status | Estimated completion date |
|---|---|---|---|---|---|---|
| Nivolumab + Ipilimumab | 1100 | Advanced NSCLC | IV | NCT02869789 | Recruiting | June 2020 |
| Nivolumab + Ipilimumab | 50 | Anti-PD-1-axis therapy-resistant advanced non-small cell lung cancer | II | NCT03262779 | Recruiting | November 2020 |
| Nivolumab + Ipilimumab + Nintedanib | 98 | Non small cell lung cancer | I/II | NCT03377023 | Recruiting | February 2021 |
| Nivolumab + Ipilimumab | 108 | After concurrent chemoradiation in patients with unresectable stage III NSCLC | II | NCT03285321 | Recruiting | September 2022 |
| Pembrolizumab + Ipilimumab | 57 | Advanced NSCLC/extensive-disease small cell lung cancer (MK-3475-011/KEYNOTE-011) | I | NCT01840579 | Active, not recruiting | June 2020 |
| Nivolumab + Ipilimumab | 504 | Advanced non-small cell lung cancer (FRACTION-Lung) | II | NCT02750514 | Active, not recruiting | April 2021 |
| Nivolumab + Ipilimumab | 30 | Resectable non-small-cell lung cancer | II | NCT02259621 | Recruiting | January 2023 |
| Nivolumab + Ipilimumab | 24 | Pretreated advanced stage non-small cell lung cancer patients | I | NCT03509584 | Not yet recruiting | April 2021 |